Berhyanda Limited files Regulation 31(4) disclosure for substantial acquisition in Cohance Lifesciences

M&A / JV 23 Jun 2026 · Filed / open· ✓ Verified

Berhyanda Limited has made a regulatory disclosure to NSE under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 31(4). This regulation mandates disclosure when a person acquires shares that result in aggregate shareholding crossing defined thresholds (typically 25%, 50%, or 75%). The filing confirms the acquirer's intention to comply with open offer requirements if applicable.

Why it mattersA Reg 31(4) disclosure signals that an acquirer has crossed the statutory 25% threshold triggering open offer obligations; counsel must immediately review the disclosure for trigger-crossing details, exemption claims, and the timeline and mechanics for the mandatory offer.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals